exRNAdisease

Entry Detail

---



General Information

Database ID: exR0356637 RNA Name: hsa-miR-296-3p RNA Type: miRNA Chromosome: chr20 Starnd: - Coordinate: Start Site(bp): 58817626 End Site(bp): 58817647 External Links: hsa-miR-296-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ATXN7 chr3 63864557 64003462 + BAZ2A chr12 56595596 56636816 - COL6A1 chr21 45981769 46005050 + CYLD chr16 50742050 50801935 + FAM210A chr18 13663347 13726663 - HMGCS1 chr5 43287470 43313512 - HOXC10 chr12 53985065 53990279 + HP1BP3 chr1 20740266 20787323 - KAT6A chr8 41929479 42051994 - KMT2D chr12 49018975 49059774 - KPNA6 chr1 32108056 32176563 + LASP1 chr17 38869859 38921770 + MINK1 chr17 4833340 4898061 + NFAT5 chr16 69565094 69704666 + PFN2 chr3 149964904 150050788 - RTKN chr2 74425835 74442422 - SERF2 chr15 43777087 43802589 + SLC2A4RG chr20 63739776 63744050 + STK35 chr20 2101827 2177038 + TMEM97 chr17 28319200 28328685 + TP53 chr17 7661779 7687550 - TULP3 chr12 2877223 2941138 + UBA2 chr19 34428352 34471251 + VANGL1 chr1 115641970 115698224 + ZFP91 chr11 58579063 58621550 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001867 chr9 86294689 86297981 - hsa_circ_0001866 chr9 86293355 86297981 - hsa_circ_0001046 chr2 97024782 97033111 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + AC016831.1 chr7 130876809 130913310 - AC023509.1 chr12 53441741 53467528 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - PCBP2-OT1 chr12 53464468 53465057 + SNHG25 chr17 64145970 64146476 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.